Values First Advisors Inc. Makes New Investment in Cogent Biosciences, Inc. (NASDAQ:COGT)

Values First Advisors Inc. purchased a new stake in Cogent Biosciences, Inc. (NASDAQ:COGT) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 2,962 shares of the technology company’s stock, valued at approximately $32,000.

A number of other hedge funds also recently made changes to their positions in COGT. Russell Investments Group Ltd. raised its position in Cogent Biosciences by 234.5% in the first quarter. Russell Investments Group Ltd. now owns 10,014 shares of the technology company’s stock worth $67,000 after purchasing an additional 7,020 shares in the last quarter. nVerses Capital LLC acquired a new position in shares of Cogent Biosciences in the 3rd quarter worth approximately $76,000. Quest Partners LLC acquired a new stake in shares of Cogent Biosciences during the 2nd quarter worth about $89,000. 49 Wealth Management LLC boosted its position in Cogent Biosciences by 20.5% in the first quarter. 49 Wealth Management LLC now owns 13,137 shares of the technology company’s stock valued at $91,000 after buying an additional 2,236 shares in the last quarter. Finally, SkyView Investment Advisors LLC increased its holdings in shares of Cogent Biosciences by 25.0% during the second quarter. SkyView Investment Advisors LLC now owns 12,500 shares of the technology company’s stock worth $105,000 after buying an additional 2,500 shares in the last quarter.

Wall Street Analyst Weigh In

COGT has been the topic of a number of research analyst reports. Citigroup increased their price target on Cogent Biosciences from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Robert W. Baird upped their target price on shares of Cogent Biosciences from $8.00 to $10.00 and gave the company a “neutral” rating in a research report on Thursday, September 5th. JPMorgan Chase & Co. reduced their target price on Cogent Biosciences from $22.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, August 7th. HC Wainwright lowered their price target on Cogent Biosciences from $19.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. Finally, Wedbush reiterated a “neutral” rating and issued a $11.00 price target (up from $10.00) on shares of Cogent Biosciences in a research report on Tuesday, September 3rd. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Cogent Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $14.67.

Cogent Biosciences Trading Down 0.3 %

NASDAQ:COGT opened at $11.97 on Friday. Cogent Biosciences, Inc. has a 1 year low of $3.67 and a 1 year high of $12.61. The stock has a 50-day moving average price of $10.90 and a two-hundred day moving average price of $9.11. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of -4.83 and a beta of 1.71.

Cogent Biosciences (NASDAQ:COGT) last posted its earnings results on Tuesday, August 6th. The technology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). During the same period last year, the company earned ($0.59) earnings per share. Sell-side analysts forecast that Cogent Biosciences, Inc. will post -2.25 earnings per share for the current year.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.